Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Non-Current Deffered Revenue (2016 - 2025)

Historic Non-Current Deffered Revenue for Regenxbio (RGNX) over the last 8 years, with Q3 2025 value amounting to $21.2 million.

  • Regenxbio's Non-Current Deffered Revenue changed N/A to $21.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.2 million, marking a year-over-year change of. This contributed to the annual value of $3.8 million for FY2020, which is 1350.14% up from last year.
  • Latest data reveals that Regenxbio reported Non-Current Deffered Revenue of $21.2 million as of Q3 2025.
  • Over the past 5 years, Regenxbio's Non-Current Deffered Revenue peaked at $26.3 million during Q1 2025, and registered a low of $3.5 million during Q3 2021.